Our Board of Directors
Rob Michiels was elected as chairman of the Company's Board of Directors in 2016. He is a 30+-year veteran of the US medical device industry, both in corporate positions and as a serial start-up entrepreneur. He most recently served as CEO of CardiAQ™ Valve Technologies, a venture-funded start-up developing transcatheter mitral valve implantation that was acquired by Edwards Lifesciences in 2015. He previously served as president and COO of CoreValve and as president and COO of InterVentional Technologies. He helped develop both companies from cardiovascular start-ups into established market leaders creating and marketing new and innovative interventional technologies that have strong synergies with the FEops story. Rob is also a founding partner of CONSILIUM Associates, a medical device market research company active in identifying, funding and greenhousing start-up technologies. Fluent in English, French and Dutch, he holds a bachelor's degree in economics from Antwerp University in Belgium and an MBA from Indiana University.
Tom worked with Boston Scientific Corporation for 21 years, most recently as VP and general manager of transcatheter aortic valves (TAVI) from 2012 – 2017. He was responsible for leading Boston Scientific into the global market for minimally invasive transcatheter aortic valves and was closely involved with the new business development strategy for the structural heart area. He holds a bachelor of science in business from the University of Minnesota, Minneapolis with concentration in marketing and logistics.
Guillaume is investment manager at Valiance, a London-based investment firm. He is responsible for its portfolio of life sciences companies, investing growth capital into innovative medical technologies in Europe and in the US. Prior to that, Guillaume worked in investment banking, advising large capitalization corporations on mergers and acquisitions and other corporate finance decisions, including capital market financing. He has experience in various sectors, including healthcare, consumer, retail, telecom, e-commerce and oil & gas. He graduated from ESSEC Business School in Paris.
Marc Lambrechts is senior investment manager at Capricorn Venture Partners NV. Marc’s investment interests are related to technology fusion, specifically ICT, digital healthcare, IoT and nanotechnology. Marc oversaw successful investments in a.o., Enfocus, FillFactory and Punch Powertrain. He serves on the board of FEops, Bluebee and Leuven.Inc. Prior to joining Capricorn Venture Partners in March 1998, Marc served for six years as senior scientific adviser at IWT and worked for two years at the European R&D lab of Terumo Europe NV. Marc has a PhD in electrical engineering from the University of Leuven with a focus on implantable biosensors.
Kenneth Wils is an all-round finance and venture capital professional with a passion for life sciences and healthcare. Kenneth started his career at Fortis Bank (currently BNP Paribas), where eventually he became Equity Analyst for Fortis Merchant Banking, responsible for the coverage of European chemical stocks and Belgian biotechnology related stocks. In 2004, he joined Ernst and Young Transaction Advisory. As Corporate Finance Manager he offered financial advisory services to SME/private equity funds on transaction related aspects. In 2007, he joined PMV, where he was primarily active as seed and early stage venture capital provider to innovative start-ups, with a focus on life sciences and healthcare. He also served as board member in several successful technology start-ups and funds. In 2013 he was invited by the Foederer group to strengthen their consultancy team as independent advisor with a focus on pharmacies, medical professions and healthcare. After five years Kenneth returned to the venture capital industry. He is now Senior Investment Manager at the PMV Life Sciences team. Kenneth obtained his master's degree in Chemical Engineering - Process Technology at the KUL (Catholic University Louvain) in 1997, followed by a postgraduate in Industrial Economics in 1998. He got an MBA in General Management at the Vlerick Leuven Gent Management School in 2003.
Under Matthieu’s leadership, FEops has transformed from a small academic spin-off into a fast-growing venture capital backed gazelle in the medtech sector. He completed his degree in engineering at the University of Ghent in 2002 and gained his PhD in 2008 for his research on cardiovascular device and procedure modeling.
Peter is internationally recognized for his groundbreaking work in the use of computer simulations to evaluate cardiovascular implants and procedures. Under his supervision, the TAVIguide™ tool has been transformed from an innovative idea into a CE-marked product. Peter has a PhD in biomedical engineering from Ghent University.